Current and historical daily PE Ratio for Nicox (
NICXF
) from 1990 to Apr 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Nicox stock (NICXF) PE ratio as of Apr 28 2024 is 0.
More Details
Nicox SA (NICXF) PE Ratio (TTM) Chart
Nicox SA (NICXF) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1215
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Nicox PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-04-01 | At Loss | 2024-01-25 | At Loss |
| 2024-03-28 | At Loss | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
| 2024-03-22 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
| 2024-03-15 | At Loss | 2024-01-10 | At Loss |
| 2024-03-14 | At Loss | 2024-01-09 | At Loss |
| 2024-03-13 | At Loss | 2024-01-08 | At Loss |
| 2024-03-12 | At Loss | 2024-01-05 | At Loss |
| 2024-03-11 | At Loss | 2024-01-04 | At Loss |
| 2024-03-08 | At Loss | 2024-01-03 | At Loss |
| 2024-03-07 | At Loss | 2024-01-02 | At Loss |
| 2024-03-06 | At Loss | 2023-12-29 | At Loss |
| 2024-03-05 | At Loss | 2023-12-28 | At Loss |
| 2024-03-04 | At Loss | 2023-12-27 | At Loss |
| 2024-03-01 | At Loss | 2023-12-26 | At Loss |
| 2024-02-29 | At Loss | 2023-12-22 | At Loss |
| 2024-02-28 | At Loss | 2023-12-21 | At Loss |
| 2024-02-27 | At Loss | 2023-12-20 | At Loss |
| 2024-02-26 | At Loss | 2023-12-19 | At Loss |
Nicox SA (NICXF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Nicox SA
ISIN : FR0013018124
Share Class Description:
NICXF: Share from reverse splitDescription
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers